According to German and U.S. researchers, 95 percent of patients have been cured of Hepatitis C during clinical trials. The drug also proven to be effective on past patients who failed other treatments.
More than three million people suffer from the disease that causes cancer and liver cirrhosis. The disease can be passed through bodily fluid exchange and blood. Researchers are seeking approval for the drug, which has been labeled ABT-450, by U.S. Food and Drug Administration.
Researchers are anticipating the competition with another hepatitis C drug, which reportedly cost $1,000 daily. The new drug, ABT-450 is better tolerated according to researchers, compared to interferon, the traditional fighting drug for hepatitis C.
The new drug has been deemed a breakthrough and lead researcher, Dr. Stefan Zeuzem says, “Interferon is no longer required to cure hepatitis C.” Zeuzem is a professor of medicine at the J.W. Goethe University Hospital in Frankfurt Germany.
The manufactures for ABT-450 are developers AbbVie, which also funded the study carried out by the German doctors. The findings were published in the New England Journal of Medicine and later shared in the meeting for European Association for the Study of the Liver in London.
One of the advantages discussed regarding the new drug is that it is a pill that works a lot sooner than a weekly injection of interferon. Other treatments reportedly take up to a year to began working while ABT-450 only takes three months. Interferon also has flu-like side effects and fatigue.
The downside to the new drug is it’s possible pricey cost. The price for ABT-450 is still unclear but reportedly it is expected to be high. Critics hope that the price is reasonable, otherwise patients would decline the new miracle cure.